Hot Investor Mandate 2: European Life Science VC Invests in Early Stage Biotech and Devices

~ Next Phase Admin ~ Leave a comment

A venture capital firm based in Europe that focuses solely on the life sciences is investing from their third fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S.

The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Medical Technology Fund Looks Globally for Precision Medicine Opportunities

~ Next Phase Admin ~ Leave a comment

A medical technology venture firm based in New England makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Japan Based Pharma Looks Overseas for Pharma, Device and Home Healthcare Innovations

~ Next Phase Admin ~ Leave a comment

A pharma firm headquartered in Tokyo, Japan focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The firm has existing businesses in respiratory diseases, cardiovascular disease, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The firm is also interested in home patient monitoring products. In addition, the firm is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which are all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the firm is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the firm is looking for late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases. The firm is most interested in small molecule and peptide drugs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Must See Video—CEOs explain sourcing Family Offices, Working Your Pipeline and Cost of Campaigns – Tales from the Road at RESI

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

More frequently than not LSN captures content through its RESI panels that hits the nail on the head. The recent “Tales from the Road” Panel does just that. It’s 6 minutes long but worth a viewing it if you are a scientist-entrepreneur or fundraising CEO. The most vital take-aways include how to source potential investors (particularly family offices), the process of “working” your pipeline of investors, and the costs associated with conducting a successful campaign.

The panel brought together successful biotech and medtech entrepreneurs to tell their stories of successfully raising capital. These are seasoned entrepreneurs who have been there done that and collectively have raised numerous private financing rounds and have exited multiple companies, with combined total deals exceeding $750 MM. They came to RESI San Diego to share their wisdom to fellow fundraising executives and provide insight in order to help their peers succeed.

RESI Premier Partnering Plus – An In Depth Look At RESI’s New Enhanced Partnering Service

~ Next Phase Admin ~ Leave a comment

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

In last week’s Next Phase newsletter, LSN announced the new Premier Partnering Plus service for RESI attendees.  This week, we’d like to give you a more in depth look at how Premier Partnering Plus will take RESI Partnering to the next level, and show you an example of the extra information that will be available to attendees who opt for the Premier Partnering Plus pass.  RESI Early Bird rates end on Friday, so now is the time to sign up.

Premier Partnering Plus users will receive:

  • Detailed investment and deal mandate information to help dial in who they need to meet with based on fit
  • Include specifics on the sectors and subsectors
  • Indication interest, company and management team requirements
  • Contact information and best way to reach out to an investor

Below, you can take a look at an example of what Premier Partnering Plus attendees will be able to see once RESI Partnering launches.

This a first for integrating a world class investor & strategic data platform with a partnering application, and will make attendees who use the service much more selective, efficient and successful in their partnering activities.

(Click to watch LSN Investor Platform intro video)

Calling All Life Science Entrepreneurs – Enter the RESI Boston Innovation Challenge

~ Next Phase Admin ~ Leave a comment

By Chris Cummings, Senior Business Development Manager, LSN

Christine A. Wu, Senior Research Analyst, LSN

chrsitineRESI is coming home to Boston and so is the RESI Innovation Challenge. This September’s life science innovation competition will showcase the most promising new health technologies in the RESI Innovation Challenge. If you are fundraising and aim to build a presence in the Boston’s booming healthcare scene, we’d like to see your application.

The RESI Innovation Challenge invites the top-tier early-stage companies in therapeutics, medical devices, diagnostics and healthcare IT to present from around the globe. All applicants will be vetted on the crucial balance of the quality of the company’s scientific innovation and the investment potential based on the company current standings and management team.

On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to “invest” in the company whom they believe to be the most “investible” of the contestants. The top three winners with the most RESI cash will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

In the past we have seen around 50% of Innovation Challenge companies receive funding within a year from their exhibition at RESI. Be sure not to miss out on the chance of adding to this statistic – apply for the Innovation Challenge.

See below for the previous RESI Innovation Challenge testimonials.

“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”

– Herman Lo, CEO, ViewsIQ Inc.

3rd Place in San Diego IC

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

Hot Investor Mandate 1: Private Equity Firm Seeks Commercial-Stage Life Science and Healthtech Opportunities

~ Next Phase Admin ~ Leave a comment

A private equity firm based in Philadelphia, PA provides expansion and growth capital to commercial-stage companies in select healthcare sectors. The firm recently closed its first fund in June of 2016 at $200M, and is targeting initial equity investments around $10M with up to another $5M-$10M in additional capital reserved for follow-on investments. The partners of the firm have significant experience investing in and building healthcare companies, and look to leverage their operational experience to help portfolio companies grow and scale. The firm is focused on US-based companies, and prefers to lead rounds but will also participate as a minority investor in a syndicate. The firm is targeting 3-4 investments per year.

The firm is focused on commercial-stage companies within specialty pharmaceutical, medical technology, healthcare services and digital health that are generating at least $5M in revenue. It is not a requirement that the company have positive EBITDA, but should be anticipating positive cash flow within 18 months. 1315 Capital has particular interest in obesity prevention, opioid addiction, podiatry and cosmeceuticals.

The firm prefers to work with experienced management teams and typically avoids first time entrepreneurs, but will evaluate companies with a great product and complete management team. The firm prefers to work with companies that have more than one product. The firm does seek a board seat along with investment and prefers to be involved with the management team, given the firm’s expertise in operations and ability to directly help the company scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com